Also known as lonapegsomatropin-tcgd, Skytrofa, ACP 011
Lonapegsomatropin, sold under the brand name Skytrofa, is a human growth hormone used for the treatment of growth hormone deficiency. Lonapegsomatropin is a prodrug of somatropin.
Lonapegsomatropin, sold under the brand name Skytrofa, is a human growth hormone used for the treatment of growth hormone deficiency. Lonapegsomatropin is a prodrug of somatropin.
Lonapegsomatropin was approved for medical use in the United States in August 2021, and in the European Union in January 2022.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).